Back to search

Peptide record

TPDB08611

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08611
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia SATPdb dbACP Antifungipept dbAMP 3.0 AI4AVP DRAVP 2.0 APD_complete PD_Hemolysis
standard
No
A 17-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, SATPdb, and other sources, with an available 3D structural model.
Sequence
GFKRIVQRIKDFLRNLV
Physicochemical Analysis
C97H164N30O22
ACEHMPSTWY
R
2102.56
12.13
5
1
8
+4
2.79
-0.094
125.88
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
0
A
3
R
1
N
1
D
0
C
0
E
1
Q
1
G
0
H
2
I
2
L
2
K
0
M
2
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 3 N: 1 D: 1 C: 0 E: 0 Q: 1 G: 1 H: 0 I: 2 L: 2 K: 2 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
17
C97H164N30O22
2102.56
12.13
+4
2.79
-0.094
Evidence Records 17 records
Evidence 1 Activity

Activity

MIC
Antibacterial
3.1-6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

NA

Other

Active against E. coli ATCC 25922, K. pneumonia ATCC 13883, P. aeruginosa PAO1, and S. aureus USA300 MRSA (MIC 3.1-6.2 uM). More active against a mprF mutant strain (Golla R. et al., 2020). Virus: inhibited Human
Evidence 2 Activity

Activity

MIC
Antifungal
3.1-6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

Antifungipept

Other

Active against E. coli ATCC 25922, K. pneumonia ATCC 13883, P. aeruginosa PAO1, and S. aureus USA300 MRSA (MIC 3.1-6.2 uM). More active against a mprF mutant strain (Golla R. et al., 2020). Virus: inhibited Human
Evidence 3 Activity

Activity

MIC
Antiparasitic
3.1-6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP 3.0

Other

Source Activity Label Source Definition
Antiparasitic
dbAMP 3.0 classified under the Anti-parasitic function class.
Active against E. coli ATCC 25922, K. pneumonia ATCC 13883, P. aeruginosa PAO1, and S. aureus USA300 MRSA (MIC 3.1-6.2 uM). More active against a mprF mutant strain (Golla R. et al., 2020). Virus: inhibited Human
Evidence 4 Activity

Activity

MIC
Antiviral
3.1-6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
Active against E. coli ATCC 25922, K. pneumonia ATCC 13883, P. aeruginosa PAO1, and S. aureus USA300 MRSA (MIC 3.1-6.2 uM). More active against a mprF mutant strain (Golla R. et al., 2020). Virus: inhibited Human
Evidence 5 Activity

Activity

50% cell death
Toxicity
8.9 µM
Cytotoxic
50% cell death | 8.9 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins | Antimicrob Agents Chemother | 2008
Evidence 6 Activity

Activity

50% Cell death
Toxicity
10.8 µM
Cytotoxic
50% Cell death | 10.8 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
50% Hemolysis | 160 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Arginine-lysine positional swap of the LL-37 peptides reveals evolutional advantages of the native sequence and leads to bacterial probes. | Biochim Biophys Acta | 2017
Evidence 8 Activity

Activity

50% Cell death
Toxicity
75 µM
Cytotoxic
50% Cell death | 75 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Arginine-lysine positional swap of the LL-37 peptides reveals evolutional advantages of the native sequence and leads to bacterial probes. | Biochim Biophys Acta | 2017
Evidence 9 Activity

Activity

50% Cell death
Toxicity
35 µM
Cytotoxic
50% Cell death | 35 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Arginine-lysine positional swap of the LL-37 peptides reveals evolutional advantages of the native sequence and leads to bacterial probes. | Biochim Biophys Acta | 2017
Evidence 10 Activity

Activity

18% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
18% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Amino Acid Composition Determines Peptide Activity Spectrum and Hot-Spot-Based Design of Merecidin. | Adv Biosyst | 2018
Evidence 11 Activity

Activity

67% Hemolysis
Toxicity
200 µM
Hemolytic Cytotoxic
67% Hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Amino Acid Composition Determines Peptide Activity Spectrum and Hot-Spot-Based Design of Merecidin. | Adv Biosyst | 2018
Evidence 12 Activity

Activity

50% Cytotoxicity
Toxicity
>50 µM
Cytotoxic
50% Cytotoxicity | >50 | µM | target cell: Human primary macrophages

Target

Human primary macrophages

Source & Reference

NA
DBAASP
Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection. | iScience | 2021
Evidence 13 Activity

Activity

14.4% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
14.4% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides | Toxics | 2024
Evidence 14 Activity

Activity

LC50
Toxicity
22 µM
Cytotoxic
LC50 | 22 | µM | target cell: Human bronchial epithelial cells BEAS-2B

Target

Human bronchial epithelial cells BEAS-2B

Source & Reference

NA
DBAASP
A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides | Toxics | 2024
Evidence 15 Activity

Activity

LC
Toxicity
50 µM
Cytotoxic
LC | 50 | µM | target cell: Human bronchial epithelial cells BEAS-2B

Target

Human bronchial epithelial cells BEAS-2B

Source & Reference

NA
DBAASP
A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides | Toxics | 2024
Evidence 16 Activity

Activity

68.5% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
68.5% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides | Toxics | 2024
Evidence 17 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.